Pretreatment demographic, hematologic, and cytogenetic characteristics of 18 V-form APL patients on Intergroup protocol 0129
| UPN . | Age . | Gender . | PS . | WBC . | Blood P/B% . | Marrow P/B% . | Karyotype . |
|---|---|---|---|---|---|---|---|
| C132 | 22 | F | 0 | 1.8 | 36 | 55 | 46,XX,t(15;17)(q22;q12)[20] |
| C205 | 23 | F | 1 | 4.8 | 36 | 47 | 46,XX,t(15;17)(q22;q12)[20] |
| S448 | 35 | M | 2 | 7.4 | 73 | 83 | 46,XY,add(7)(q31),t(15;17)(q22;q12)[20] |
| S444 | 25 | F | 0 | 2.0 | 0 | 38 | 46,XX/46,XX,t(15;17)(q22;q12)[20] |
| E076 | 19 | M | 0 | 7.3 | 83 | NA | 46,XY,del(9)(q12q22),t(15;17)(q22;q12)[15]/46,XY[5] |
| C902 | 25 | M | 0 | 0.9 | 0 | 92 | 46,XY,t(15;17)(q22;q12)[19]/46,XY[1] |
| E003 | 66 | F | 3 | 63.1 | 59 | 84 | 46,XX[8] |
| E011 | 32 | F | 0 | 77.4 | 95 | 91 | 46,XX[97]/47,XX,+13[3] |
| E801 | 36 | F | 0 | 0.7 | 23 | 90 | NA |
| E036 | 31 | M | 1 | 2.3 | 1 | NA | 46,XY,t(15;17)(q22;q12)[9]/46,XY[11] |
| E086 | 29 | F | 1 | 68.6 | 85 | 90 | 46,XX,t(15;17)(q22;q12)[17]/46,XX[18] |
| S386 | 41 | F | 0 | 1.1 | 0 | 34 | NA |
| E805 | 19 | F | 0 | 3.3 | NA | 75 | 46,XX,t(15;17)(q22;q12)[20] |
| C179 | 37 | M | 1 | 11.0 | 77 | 88 | 47,XY,+8,t(15;17)(q22;q12)[17]/46,XY,der(15)t(8;15)(q13;p11), t(15;17)(q22;q12),der(22)t(8;22)(q13;p11)[12]/46,XY[1] |
| E027 | 44 | M | 0 | 5.7 | 56 | NA | 46,XY,t(15;17)(q22;q12)[20] |
| E091 | 57 | M | 3 | 1.7 | 0 | 80 | 46,XY,t(15;17)(q22;q12)[17]/46,XY[3] |
| C183 | 41 | F | 0 | 12.7 | 50 | NA | NA |
| E070 | 43 | M | 0 | 0.9 | 30 | 90 | 47,XY,+8,t(15;17)(q22;q12)[20] |
| UPN . | Age . | Gender . | PS . | WBC . | Blood P/B% . | Marrow P/B% . | Karyotype . |
|---|---|---|---|---|---|---|---|
| C132 | 22 | F | 0 | 1.8 | 36 | 55 | 46,XX,t(15;17)(q22;q12)[20] |
| C205 | 23 | F | 1 | 4.8 | 36 | 47 | 46,XX,t(15;17)(q22;q12)[20] |
| S448 | 35 | M | 2 | 7.4 | 73 | 83 | 46,XY,add(7)(q31),t(15;17)(q22;q12)[20] |
| S444 | 25 | F | 0 | 2.0 | 0 | 38 | 46,XX/46,XX,t(15;17)(q22;q12)[20] |
| E076 | 19 | M | 0 | 7.3 | 83 | NA | 46,XY,del(9)(q12q22),t(15;17)(q22;q12)[15]/46,XY[5] |
| C902 | 25 | M | 0 | 0.9 | 0 | 92 | 46,XY,t(15;17)(q22;q12)[19]/46,XY[1] |
| E003 | 66 | F | 3 | 63.1 | 59 | 84 | 46,XX[8] |
| E011 | 32 | F | 0 | 77.4 | 95 | 91 | 46,XX[97]/47,XX,+13[3] |
| E801 | 36 | F | 0 | 0.7 | 23 | 90 | NA |
| E036 | 31 | M | 1 | 2.3 | 1 | NA | 46,XY,t(15;17)(q22;q12)[9]/46,XY[11] |
| E086 | 29 | F | 1 | 68.6 | 85 | 90 | 46,XX,t(15;17)(q22;q12)[17]/46,XX[18] |
| S386 | 41 | F | 0 | 1.1 | 0 | 34 | NA |
| E805 | 19 | F | 0 | 3.3 | NA | 75 | 46,XX,t(15;17)(q22;q12)[20] |
| C179 | 37 | M | 1 | 11.0 | 77 | 88 | 47,XY,+8,t(15;17)(q22;q12)[17]/46,XY,der(15)t(8;15)(q13;p11), t(15;17)(q22;q12),der(22)t(8;22)(q13;p11)[12]/46,XY[1] |
| E027 | 44 | M | 0 | 5.7 | 56 | NA | 46,XY,t(15;17)(q22;q12)[20] |
| E091 | 57 | M | 3 | 1.7 | 0 | 80 | 46,XY,t(15;17)(q22;q12)[17]/46,XY[3] |
| C183 | 41 | F | 0 | 12.7 | 50 | NA | NA |
| E070 | 43 | M | 0 | 0.9 | 30 | 90 | 47,XY,+8,t(15;17)(q22;q12)[20] |
UPN indicates unique patient number; PS, performance status (ECOG); WBC, white blood cell count prior to any cytoreductive therapy (×103/L); P, promyelocytes; B, blasts; NA, not available.